Klaus G Klumpp

USPTO Granted Patents = 12 (Patent Applications = 10)

CIPO Patents = 3 (Patent Applications = 1)

EPO Patents = 4 (Patent Applications = 5)

Average Co-Inventor Count = 2.2

ph-index = 3

Forward Citations = 13(Granted Patents)

Location History:

Sunnyvale, CA (US) (2020)
West Chester, PA (US) (2016 - 2021)
Palo Alto, CA (US) (2021 - 2024)

Company Filing History:

Novira Therapeutics, Inc.

patents

2 out of 60

Janssen Sciences Ireland Unlimited Company

patents

where one patent can have more than one assignee

Years Active: 2016-2024

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12029744 - Bicyclic heteroaryl derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors (2024-07-09),

2. 11351186 - 4'-fluoro-2′-methyl substituted nucleoside derivatives as inhibitors of HCV RNA replication (2022-06-07),

3. 11129834 - Combinations and methods comprising a capsid assembly inhibitor (2021-09-28),

4. 10953030 - 4'-fluoro-2′-methyl substituted nucleoside derivatives as inhibitors of HCV RNA replication (2021-03-23),

5. 10682369 - 4'-fluoro-2′-methyl substituted nucleoside derivatives as inhibitors of HCV RNA replication (2020-06-16),

6. 10441589 - Combinations and methods comprising a capsid assembly inhibitor (2019-10-15),

7. 10358458 - 4'-vinyl substituted nucleoside derivatives as inhibitors of respiratory syncytial virus RNA replication (2019-07-23),

8. 10092649 - 4'-difluoromethyl substituted nucleoside derivatives as inhibitors of influenza RNA replication (2018-10-09),

9. 9895442 - 4'-fluoro-2′-methyl substituted nucleoside derivatives as inhibitors of HCV RNA replication (2018-02-20),

10. 9694028 - 4'-azido, 3′-deoxy-3′-fluoro substituted nucleoside derivatives as inhibitors of HCV RNA replication (2017-07-04),

11. 9370569 - 4'-difluoromethyl substituted nucleoside derivatives as inhibitors of influenza RNA replication (2016-06-21),

12. 9249176 - 4'-azido, 3′-deoxy-3′-fluoro substituted nucleoside derivatives as inhibitors of HCV RNA replication (2016-02-02),

Title: Klaus G Klumpp: Innovator in Pharmaceutical Advancements

Introduction

Klaus G Klumpp is a distinguished inventor based in Sunnyvale, CA, known for his significant contributions to the field of pharmaceuticals. With a portfolio of 12 patents, Klumpp's work has paved the way for advancements in treating complex diseases by targeting specific enzymatic pathways.

Latest Patents

Among Klumpp's latest patents are groundbreaking compounds aimed at inhibiting enzymatic activities critical for various therapeutic applications. One notable patent focuses on "Bicyclic heteroaryl derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors." This patent details certain bicyclic heteroaryl compounds that effectively inhibit the enzymatic activity of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), which plays a role in several diseases. Additionally, another patent describes "4'-fluoro-2'-methyl substituted nucleoside derivatives as inhibitors of HCV RNA replication." This invention presents cytidine nucleoside analogues in combination with uridine nucleoside analogues to create a synergistic effect that inhibits HCV polymerase.

Career Highlights

Klumpp has had a remarkable career, marked by his tenure at prominent companies such as Riboscience LLC and Novira Therapeutics, Inc. His experience in these organizations has allowed him to develop innovative therapies that address critical public health challenges.

Collaborations

Throughout his career, Klaus G Klumpp has collaborated with notable professionals, including Mark Smith and George D Hartman. These partnerships have facilitated knowledge exchange and fostered innovative approaches to drug development.

Conclusion

Klaus G Klumpp stands out as a leading inventor in the pharmaceutical sector, with a commendable track record of patents that contribute to medical advancements. His ongoing work continues to impact the treatment of diseases, showcasing the vital role of innovation in healthcare.

This text is generated by artificial intelligence and may not be accurate.